meta
|
evidence
oncology
Living systematic review and meta-analysis
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - all population
2
MIBC - NA - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs placebo
All patients
PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DMFS
events or deaths (EFS)
RFS/DFS
DMFS
MIBC - NA - PDL1 positive
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - PDL1 positive
versus placebo
nivolumab alone vs. placebo
1
certainty unassessable
-36%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open